Search results for "Cholesterol"

showing 10 items of 1211 documents

Effects of n-3 Polyunsaturated Fatty Acids (ω-3) Supplementation on Some Cardiovascular Risk Factors with a Ketogenic Mediterranean Diet

2015

Background: the ketogenic diet (KD) has become a widely used nutritional approach for weight loss. Some of the KD’s positive effects on metabolism and cardiovascular risk factors are similar to those seen after n-3 polyunsaturated fatty acids (ω-3) supplementation. We hypothesized that a ketogenic Mediterranean diet with phytoextracts combined with ω-3 supplementation may have increased positive effects on cardiovascular risk factors and inflammation. Methods: We analyzed 34 male overweight subjects

cardiovascular risk factorsBlood GlucoseMaleMediterranean dietinflammatory cytokinesmedicine.medical_treatmentN-3 polyunsaturated fatty acidPharmaceutical ScienceOverweightDiet Mediterraneanchemistry.chemical_compoundRisk FactorsWeight lossDrug DiscoveryInsulinlcsh:QH301-705.5Pharmacology Toxicology and Pharmaceutics (miscellaneous)Adipositychemistry.chemical_classificationCardiovascular risk factors; Inflammatory cytokines; Ketogenic diet; N-3 polyunsaturated fatty acids; Omega-3; Weight loss; Drug Discovery3003 Pharmaceutical ScienceMiddle Agedn-3 polyunsaturated fatty acidsketogenic dietCardiovascular DiseasesCytokinesomega-3medicine.symptomDiet KetogenicPolyunsaturated fatty acidAdultmedicine.medical_specialtyInflammatory cytokineBiologyCardiovascular risk factorWeight loArticleInternal medicineFatty Acids Omega-3Weight LossmedicineHumansTriglyceridesAgedAdiponectinPlant ExtractsCholesterolDrug Discovery3003 Pharmaceutical Science<i>n</i>-3 polyunsaturated fatty acidsCholesterol LDLOverweightEndocrinologylcsh:Biology (General)chemistryDietary SupplementsUric acidKetogenic dietMarine Drugs
researchProduct

Lifestyle and impact on cardiovascular risk factor control in coronary patients across 27 countries: Results from the European Society of Cardiology …

2019

Aims The aim of this study was to determine whether the Joint European Societies guidelines on secondary cardiovascular prevention are followed in everyday practice. Design A cross-sectional ESC-EORP survey (EUROASPIRE V) at 131 centres in 81 regions in 27 countries. Methods Patients (&lt;80 years old) with verified coronary artery events or interventions were interviewed and examined ≥6 months later. Results A total of 8261 patients (females 26%) were interviewed. Nineteen per cent smoked and 55% of them were persistent smokers, 38% were obese (body mass index ≥30 kg/m2), 59% were centrally obese (waist circumference: men ≥102 cm; women ≥88 cm) while 66% were physically active &lt;30 min 5…

cardiovascular risk factorsMaleCardiac & Cardiovascular SystemsHeart diseaseEpidemiologymedicine.medical_treatmentHealth StatusEUROASPIRE ; cardiovascular risk factors ; guidelines ; lifestyle ; secondary preventionRisk Reduction Behavior*HSM CARRisk FactorsSecondary PreventionARTERY-DISEASEMyocardial infarctionEUROASPIREguidelinesDiet / adverse effectsRegistriesCardiovascular Diseases / physiopathology1102 Cardiorespiratory Medicine and HaematologyHydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use*Smoking / epidemiologySmokingHealthy Lifestyle*Middle AgedPREVALENCEEuropeCardiovascular Diseases / diagnosisTreatment OutcomeCardiovascular DiseasesCardiovascular Agents / therapeutic use*LDL Cholesterol LipoproteinsFemaleEurope / epidemiologyCardiology and Cardiovascular MedicineLife Sciences & Biomedicinesecondary preventionmedicine.medical_specialtylifestyleSmoking / adverse effectsCardiovascular risk factorsHEART-DISEASERisk AssessmentLOW-INCOME COUNTRIESLife Style*Cardiovascular Diseases / prevention & control*Cardiovascular preventionmedicineJournal ArticleHumansHealthy Lifestyleddc:610Risk factorLife StyleAgedCardiovascular Diseases / epidemiologyScience & TechnologyTask forcebusiness.industryCardiovascular AgentsSMOKING-CESSATIONProtective Factorsmedicine.diseaseDietEUROASPIRE Investigators*Cross-Sectional StudiesMYOCARDIAL-INFARCTIONCLINICAL-PRACTICEFamily medicineHealth Care SurveysCardiovascular System & CardiologySmoking cessationPatient ComplianceHydroxymethylglutaryl-CoA Reductase InhibitorsSedentary BehaviorbusinessRisk Reduction BehaviorTASK-FORCE
researchProduct

Long-term positive airway pressure therapy is associated with reduced total cholesterol levels in patients with obstructive sleep apnea : data from t…

2020

Background and aim: Obstructive sleep apnea (OSA) is an independent risk factor for dyslipidemia. The current study examined the effects of positive airway pressure (PAP) treatment on lipid status in the European Sleep Apnea Database (ESADA). Methods: The prospective cohort study enrolled 1564 OSA subjects (74% male, mean age 54 ± 11y, body mass index (BMI) 32.7 ± 6.6 kg/m2 and apnea-hypopnea index (AHI) 40.3 ± 24.4 n/h) undergoing PAP therapy for at least three months (mean 377.6 ± 419.5 days). Baseline and follow-up total cholesterol (TC) from nine centers were analyzed. Repeated measures and logistic regression tests (adjusted for age, sex, weight changes, lipid lowering medication, PAP …

cardiovascular riskAdultMalemedicine.medical_specialtySettore MED/10 - Malattie Dell'Apparato RespiratorioPositive airway pressure03 medical and health sciences0302 clinical medicineInternal medicinePositive airway pressuremedicineCardiovascular risk Cholesterol Hypoxia Sleep apneaHumanspositive airway pressureProspective StudiesRisk factorProspective cohort studyHypoxiaAgedSleep Apnea ObstructiveFramingham Risk ScoreContinuous Positive Airway Pressurebusiness.industryhypoxiaSleep apneaSleep apneacholesterolGeneral MedicineMiddle Agedmedicine.diseasesleep apneaCardiovascular riskObstructive sleep apneaCardiovascular risk ; Cholesterol ; Hypoxia ; Positive airway pressure ; Sleep apnea.Cholesterol030228 respiratory systemPatient ComplianceFemaleHuman medicinebusinessBody mass index030217 neurology & neurosurgeryDyslipidemiaSleep medicine
researchProduct

Ezetimibe, cardiovascular risk and atherogenic dyslipidaemia.

2010

Ezetimibe is a selective cholesterol absorption inhibitor with an excellent side-effect profile, able to reduce low-density lipoprotein (LDL) cholesterol by 15-25% from baseline in monotherapy and on top of statins and fibrates. Yet, it seems that ezetimibe produces quantitative rather than qualitative changes in LDL, with small net effects on atherogenic dyslipidaemia. This is supported by findings from the Ezetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis Regression (ENHANCE) study on atherosclerosis progression, where the addition of ezetimibe to simvastatin in patients with heterozygous familial hypercholesterolaemia did not affect the mean change in carotid int…

cardiovascular riskAortic valvemedicine.medical_specialtydyslipidaemiamedicine.drug_classezetimibe cardiovascular risk atherosclerosis dyslipidaemiachemistry.chemical_compoundEzetimibeInternal medicineClinical endpointMedicineCholesterol absorption inhibitorcardiovascular diseasesReview Paperbusiness.industryCholesterolnutritional and metabolic diseasesGeneral Medicinemedicine.diseaseStenosismedicine.anatomical_structureEndocrinologychemistrySimvastatinCardiologylipids (amino acids peptides and proteins)atherosclerosisbusinessezetimibeLipoproteinmedicine.drug
researchProduct

Effects of statins, fibrates, rosuvastatin, and ezetimibe beyond cholesterol: the modulation of LDL size and subclasses in high-risk patients.

2007

Increasing evidence suggests that the quality-rather than just the quantity-of low-density lipoproteins (LDLs) exerts a great influence on cardiovascular risk. LDLs comprise multiple subclasses with discrete size and density, and different physicochemical composition, metabolic behaviors, and atherogenicity. Individuals generally cluster into 2 broad subgroups. Most have a predominance of large LDLs, and some have a higher proportion of small particles. Small, dense LDLs are good predictors of cardiovascular events and progression of coronary artery disease. Their predominance has been accepted as an emerging cardiovascular risk factor by the National Cholesterol Education Program Adult Tre…

cardiovascular riskRiskStatinmedicine.drug_classHypercholesterolemiasubclassePharmacologyBioinformaticschemistry.chemical_compoundClofibric AcidEzetimibemedicineHumansPharmacology (medical)Cholesterol absorption inhibitorRosuvastatinRisk factorRosuvastatin CalciumNational Cholesterol Education ProgramSulfonamidessmall dense LDLfibrateCholesterolbusiness.industryAnticholesteremic AgentsstatinGeneral MedicineCholesterol LDLEzetimibeFluorobenzenesRosuvastatin CalciumPyrimidineschemistrydiabeteCardiovascular DiseasesAzetidineslipids (amino acids peptides and proteins)Hydroxymethylglutaryl-CoA Reductase Inhibitorsbusinessrosuvastatinmedicine.drugAdvances in therapy
researchProduct

Effects of PCSK9 inhibitors on HDL cholesterol efflux and serum cholesterol loading capacity in familial hypercholesterolemia subjects: a multi-lipid…

2022

Proprotein convertase subtilisin/kexin type 9 (PCSK9), beyond regulating LDL cholesterol (LDL-c) plasma levels, exerts several pleiotropic effects by modulating lipid metabolism in extrahepatic cells such as macrophages. Macrophage cholesterol homeostasis depends on serum lipoprotein functions, including the HDL capacity to promote cell cholesterol efflux (CEC) and the serum capacity to promote cell cholesterol loading (CLC). The aim of this observational study was to investigate the effect of PCSK9 inhibitors (PCSK9-i) treatment on HDL-CEC and serum CLC in patients with familial hypercholesterolemia (FH). 31 genetically confirmed FH patients were recruited. Blood was collected and serum is…

cardiovascular riskSettore MED/09 - Medicina Internafamilial hypercholesterolemiaPCSK9 inhibitors cardiovascular risk cholesterol efflux capacity cholesterol loading capacity familial hypercholesterolemiaPCSK9 inhibitorsSettore BIO/14 - Farmacologiacholesterol loading capacityBiochemistry Genetics and Molecular Biology (miscellaneous)Molecular BiologyBiochemistrycholesterol efflux capacityPCSK9 inhibitors; cardiovascular risk; cholesterol efflux capacity; cholesterol loading capacity; familial hypercholesterolemiaFrontiers in molecular biosciences
researchProduct

Lipoprotein(a) Genotype Influences the Clinical Diagnosis of Familial Hypercholesterolemia

2023

: Background Evidence suggests that LPA risk genotypes are a possible contributor to the clinical diagnosis of familial hypercholesterolemia (FH). This study aimed at determining the prevalence of LPA risk variants in adult individuals with FH enrolled in the Italian LIPIGEN (Lipid Transport Disorders Italian Genetic Network) study, with (FH/M+) or without (FH/M-) a causative genetic variant. Methods and Results An lp(a) [lipoprotein(a)] genetic score was calculated by summing the number risk-increasing alleles inherited at rs3798220 and rs10455872 variants. Overall, in the 4.6% of 1695 patients with clinically diagnosed FH, the phenotype was not explained by a monogenic or polygenic cause …

cardiovascular risklipoprotein(a).familial hypercholesterolemia
researchProduct

Small, dense LDL: An update

2017

Purpose of review In this review, we summarize the latest findings on small, dense LDL (sdLDL) atherogenic particles, including their associations with other biomarkers. Recent findings Increased sdLDL levels have been reported not only in different metabolic disorders such as diabetes, obesity and metabolic syndrome, but also in patients with rheumatoid and psoriatic arthritis as well as hypothyroidism. A wide range of lipid-lowering, as well as other drug classes, including novel antidiabetic agents and nutraceuticals, exert favourable effects on these atherogenic particles. The 'gold standard' methodology for the assessment of sdLDL has not been established yet. However, the association …

cardiovascular riskmedicine.medical_specialtySmall dense ldl10265 Clinic for Endocrinology and Diabetology030209 endocrinology & metabolism610 Medicine & health030204 cardiovascular system & hematology2705 Cardiology and Cardiovascular Medicine03 medical and health scienceschemistry.chemical_compound0302 clinical medicineRisk FactorsInternal medicineDiabetes mellitusCardiovascular DiseaseMedicineHumansParticle SizeMetabolic Syndromebusiness.industryCholesterollipid-lowering therapieBiomarkerCholesterol LDLmedicine.diseaseAtherosclerosisObesityEndocrinologychemistrysmall dense LDLs: AtherosclerosiCardiovascular DiseasesCardiology and Cardiovascular MedicinebusinessBiomarkers
researchProduct

Hypertriglyceridemia and Omega-3 Fatty Acids

1988

Recent studies by Bang and Dyerberg (1) have stimulated interest in the metabolism of omega-3 fatty acids and have suggested a link between the ingestion of these fatty acids in a diet and the low death rate from athersclerotic disease in Eskimos. In Japan, where fish consumption has traditionally been high, a concommitant shift in tissue lipid consumption favouring omega-3 polyunsaturated fatty acids has been interpreted as causative of a relatively low incidence of cardiovascular disease (1). When analyzing Eskimo food consumption, it became clear that the consumption of omega-3 PUFA is much higher besides a 50% reduction of saturated fat and a relatively high content of monounsaturated f…

chemistry.chemical_classificationCalorieChemistrySaturated fatHypertriglyceridemiamedicineIngestionCholesterol intakeMetabolismFood sciencemedicine.diseaseOmegaPolyunsaturated fatty acid
researchProduct

The relationship between feed intake behaviour with intramuscular fat, cholesterol and fatty acid composition in pork

2011

The aim of this study was to investigate the phenotypic relationship between feed intake (FI) characteristics with intramuscular fat, cholesterol and fatty acid composition in pork. Data were available on 202 Duroc barrows. Intramuscular fatness was positively correlated with a higher percentage of saturated (SFA) and monounsaturated fatty acids (MUFA), a lower percentage of polyunsaturated (PUFA), omega-3 (ω3) and omega-6 (ω6) fatty acids, and a lower ω6/ω3 and P:S ratio (p < 0.05). Faster growth resulted in a higher level of SFA and a lower level of ω3 fatty acids (p < 0.05). Increased FI, residual feed intake (RFI) and feed intake time (TIME) and a decreased feed intake frequency (FREQ) …

chemistry.chemical_classificationCholesterolfood and beveragesGeneral MedicineBiologychemistry.chemical_compoundFeeding behaviorFood Animalschemistrylipids (amino acids peptides and proteins)Animal Science and ZoologyIntramuscular fatFatty acid compositionFood scienceResidual feed intakeLipoprotein cholesterolLipoproteinPolyunsaturated fatty acidJournal of Animal Breeding and Genetics
researchProduct